Key result
Telmisartan combined with moxonidine demonstrated high antihypertensive efficacy in a patient with arterial hypertension, obesity, dyslipidemia, and impaired fasting glycemia.
Why the study?
Guidelines recommend two antihypertensive drugs as initial therapy for arterial hypertension with overweight or obesity to mitigate increased cardiovascular risk.
Case Report (n=1)
Answers are grounded in this paper and cite their sources.
The combination of telmisartan and moxonidine may be an effective antihypertensive strategy with favorable metabolic effects for patients with hypertension and obesity.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Остроумова et al. (2020) conducted a case report in Arterial hypertension with obesity, dyslipidemia, and impaired fasting glycemia (n=1). Telmisartan combined with moxonidine was evaluated on Antihypertensive efficacy assessed by 24-hour ambulatory blood pressure monitoring. Telmisartan combined with moxonidine demonstrated high antihypertensive efficacy in a patient with arterial hypertension, obesity, dyslipidemia, and impaired fasting glycemia.
Synapse has enriched 10 related papers. Consider them for comparative context: